06:47 AM EDT, 06/05/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Thursday the phase 2 trial of its experimental therapy, dazucorilant, did not meet its primary endpoint, sending shares down 1.4% in premarket activity.

Dazucorilant is intended to treat amyotrophic lateral sclerosis, a fatal motor neuron disease.

The company said the study showed that therapy did not meet its primary endpoint of improved outcome in the ALS functional rating scale-revised in patients who received dazucorilant compared to patients who received placebo.

However, no deaths occurred in the patient group receiving 300 mg of dazucorilant compared to five deaths in the placebo group, the company said, adding that an exploratory one-year analysis also demonstrated continued survival benefit, especially for those who stayed on 300 mg for over 24 weeks.

The long-term extension study is still ongoing, the company added.

Price: 68.99, Change: -0.99, Percent Change: -1.41